Quoin Pharmaceuticals Ltd. QNRX
Quoin Pharmaceuticals Ltd. (Nasdaq: QNRX) is a dermatology drug developer. Its lead program, QRX003, is in Phase 3 for Netherton Syndrome. Its next catalyst on record is General: Shareholder meeting to amend beneficial ownership limitation (November 2026).
Upcoming catalysts
- November 2026General — Shareholder meeting to amend beneficial ownership limitation
The meeting of shareholders is scheduled to occur on November 12, 2026.
Next further out: QRX003 — Quoin expects to initiate first-ever Phase 2/3 study in Peeling Skin Syndrome before end of 2026. (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| QRX003 | Netherton Syndrome | small molecule | Phase 3 |
| QRX003 | Peeling Skin Syndrome | small molecule | Phase 2 |
| QRX009 (topical rapamycin/sirolimus) | Pachyonychia Congenita / Gorlin Syndrome / Tuberous Sclerosis Complex / other orphan indications | small molecule | Pre-clinical |
| QRX008 | Scleroderma | unclear | Pre-clinical |
Recent results and decisions
- Oct 20, 2026positive Single-patient compassionate use case report shows QRX003 improved skin from severe to clear with complete elimination of pruritus over 21 months.
After six weeks, the patient's Investigator's Global Assessment (IGA) score improved from 4 (severe) at baseline to 1 (almost clear), and itch, as measured by the Worst Itch Numeric Rating Scale (WI-NRS), was reduced from 5 to 1.
Filing - Aug 28, 2026positive Interim (first 6 pts, 12 wks, Phase 2/3 open-label baseline-controlled): primary IGA >=1-grade improvement in 4/6 (66.7%), p=0.0087 vs alpha 0.0215; no treatment-related SAEs.
Four of six (66.7%) participants achieved the target 1-grade or greater improvement across all of the treatment area in Investigator Global Assessment (IGA) from baseline at Week 12
Filing - Aug 28, 2026met QRX003 met primary endpoint and key secondary endpoint with statistical significance in interim analysis of Phase 2/3 Netherton Syndrome study.
In the interim analysis of the first six participants to complete 12 weeks of treatment, four of six (66.7%) achieved the primary endpoint of a 1-grade or greater improvement in Investigator Global Assessment (p=0.0087 vs. a pre-specified alpha of 0.0215).
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.